Alnylam Pharmaceuticals, Inc Stock News

Alnylam Pharmaceuticals NASDAQ: ALNY stock price action has been volatile but is uptrending and has gained 100% in the last two years. The uptrend is driven by increasing expectations for market-disrupting heart treatment and could double the price again.

DALLAS--(BUSINESS WIRE)--Steward Health Care (“Steward”), the country's largest physician-led, minority-owned, integrated health care system, announced today it has reached an agreement in principle with its landlord, Medical Properties Trust, Inc. (“MPT”), supported by the “FILO” secured lenders under its funded debt and the official committee of unsecured creditors. Following Bankruptcy Court...

Alnylam's stock surged due to positive HELIOS-B trial results, but lacked additional upside today after the company presented the data at the ESC congress. Amvuttra shows competitive efficacy and safety in ATTR amyloidosis, with the potential to rival Pfizer's Vyndaqel and other emerging treatments. I believe HELIOS-B's success is priced in at current levels and that further upside is limited i...

BAKERSFIELD, Calif.--(BUSINESS WIRE)--The Kern Subbasin Groundwater Sustainability Agencies (GSAs) have responded to a draft report from the California State Water Resources Control Board (SWRCB). The draft report finds the Kern subbasin's Groundwater Sustainability Plan (GSP) to be inadequate and recommends that the subbasin be placed on probation. The GSAs' response was submitted during publi...

Alnylam stock tumbled Friday after the company's Pfizer-rivaling heart disease treatment lagged expectations in a lengthy study.

Alnylam Pharmaceuticals' shares fell nearly 11% before the bell on Friday, after data for its closely watched heart drug fell short of heightened investor expectations.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: Wells Fargo 2024 Healthcare Conference on Wednesday, September 4, 2024 at 9:30 am ET in Boston Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4, 2024 a...

Investing guru Cathie Wood sees precision therapeutics as a massive growth market. She forecasts sales in the category can grow by a compound annual growth rate (CAGR) of 30% through 2030.